NCT00230542View on ClinicalTrials.gov

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

April 30, 2011

Conditions
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Interventions
DRUG

Carboplatin

Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)

DRUG

Pemetrexed

Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00230542 - Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | Biotech Hunter | Biotech Hunter